baxdrostat (CIN-107) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«123»
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Review, Journal:  Aldosterone Synthase Inhibitors and Dietary Interventions: A Combined Novel Approach for Prevention and Treatment of Cardiovascular Disease. (Pubmed Central) -  Mar 21, 2023   
    To the best of our knowledge, this is the first systematic review to summarize evidence-based articles relevant to the use of a novel drug (aldosterone synthase inhibitor) in the treatment of HTN and cardiovascular disease. Making the current database of relevant information on baxdrostat and other aldosterone synthase inhibitors readily available will, no doubt, aid physicians and other medical practitioners in their decision-making about employing aldosterone synthase inhibitors in the treatment of patients.
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Enrollment change, Trial completion date, Trial primary completion date:  spark-PA: A Study of CIN-107 in Adults With Primary Aldosteronism (clinicaltrials.gov) -  Mar 6, 2023   
    P2,  N=12, Recruiting, 
    Making the current database of relevant information on baxdrostat and other aldosterone synthase inhibitors readily available will, no doubt, aid physicians and other medical practitioners in their decision-making about employing aldosterone synthase inhibitors in the treatment of patients. N=18 --> 12 | Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023
  • ||||||||||  baxdrostat (CIN-107) / CinCor Pharma
    P2 data, Journal:  Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. (Pubmed Central) -  Nov 8, 2022   
    P2
    Patients with treatment-resistant hypertension who received baxdrostat had dose-related reductions in blood pressure. (Funded by CinCor Pharma; BrigHTN ClinicalTrials.gov number, NCT04519658.).
  • ||||||||||  firibastat (QGC-001) / Quantum Genomics, Biolab Pharma, Orient Europharma, aprocitentan (ACT-132577) / J&J, baxdrostat (CIN-107) / CinCor Pharma
    LBS.09. Late-Breaking Science: Resistant HTN: A Pressure Cooker (Main Event I) -  Sep 18, 2022 - Abstract #AHA2022AHA_6992;    
    The landscape of treatment options for resistant hypertension is expanding rapidly with the most recent clinical trials to prove it. This session includes the top line results of the first-in-class aminopeptidase-A inhibitor, firibastat (FRESH), the use of the dual endothelin receptor antagonist aprocitentan to affect underlying mechanisms for resistant HTN (PRECISION), the safety and efficacy of baxdrostat, a highly selective aldosterone synthase inhibitor (BrigHTN), and the anticipated results of radiofrequency renal denervation (SPYRAL HTN-ON).
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Trial completion:  A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) (clinicaltrials.gov) -  Sep 6, 2022   
    P2,  N=348, Completed, 
    This session includes the top line results of the first-in-class aminopeptidase-A inhibitor, firibastat (FRESH), the use of the dual endothelin receptor antagonist aprocitentan to affect underlying mechanisms for resistant HTN (PRECISION), the safety and efficacy of baxdrostat, a highly selective aldosterone synthase inhibitor (BrigHTN), and the anticipated results of radiofrequency renal denervation (SPYRAL HTN-ON). Active, not recruiting --> Completed
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Enrollment change, Trial completion date, Trial primary completion date:  spark-PA: A Study of CIN-107 in Adults With Primary Aldosteronism (clinicaltrials.gov) -  Jul 20, 2022   
    P2,  N=18, Recruiting, 
    Active, not recruiting --> Completed N=96 --> 18 | Trial completion date: Mar 2022 --> Apr 2023 | Trial primary completion date: Feb 2022 --> Mar 2023
  • ||||||||||  baxdrostat (CIN-107) / CinCor Pharma
    Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107 (Research Gateway 5) -  Jun 15, 2022 - Abstract #ESC2022ESC_3682;    
    Oral administration of CIN-107 was safe and well tolerated in all subjects and resulted in dose-dependent increases in plasma CIN-107 with a half-life that supports once-daily dosing. The dose-dependent decrease in plasma aldosterone and lack of effect on cortisol demonstrate the selective blockade of aldosterone synthase and support continued study in ongoing phase 2 clinical trials evaluating the efficacy and safety of CIN-107 for treatment-resistant or uncontrolled hypertension and primary aldosteronism.
  • ||||||||||  baxdrostat (CIN-107) / AstraZeneca
    Enrollment closed:  A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) (clinicaltrials.gov) -  May 11, 2022   
    P2,  N=348, Active, not recruiting, 
    The dose-dependent decrease in plasma aldosterone and lack of effect on cortisol demonstrate the selective blockade of aldosterone synthase and support continued study in ongoing phase 2 clinical trials evaluating the efficacy and safety of CIN-107 for treatment-resistant or uncontrolled hypertension and primary aldosteronism. Recruiting --> Active, not recruiting